^
Association details:
| Biomarker: | PD-L1 negative |
|---|---|
| Cancer: | Head and Neck Cancer |
| Drug: | budigalimab (ABBV-181) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Association of Baseline and Pharmacodynamic Biomarkers With Outcomes in Patients Treated With the PD-1 Inhibitor Budigalimab
Published date:
01/17/2022
Excerpt:
PD-1 inhibitor naive patients with advanced HNSCC (n=41) or NSCLC (n=40) received budigalimab intravenously...best overall response of 15% in HNSCC and 18% in NSCLC was observed in all treated patients; both cohorts reported responses in PD-L1+ and PD-L1– tumors.
DOI:
10.1097/CJI.0000000000000408
Trial ID:
